Treace Medical Concepts, Inc. Stock News

PONTE VEDRA, Fla., April 17, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in th

Investors who seek 50% returns in less than 12 months generally will have many choices within stable stocks. The general maxim regarding risk and return applies here: Risky, unstable stocks tend to of

Company to Host Conference Call on Tuesday, May 7, 2024 at 4:30 pm ET Company to Host Conference Call on Tuesday, May 7, 2024 at 4:30 pm ET

Treace Medical Concepts Inc (TMCI) Q4 2023 Earnings Call Transcript

Treace Medical Concepts (TMCI) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.08 per share a year ago.

Company to Host Conference Call on Tuesday, February 27, 2024 at 4:30 pm ET Company to Host Conference Call on Tuesday, February 27, 2024 at 4:30 pm ET

PONTE VEDRA, Fla., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the

Treace Medical Concepts, Inc. (NASDAQ:TMCI ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Julie Dewey - Chief Communications & Investor Relations Officer John Trea

PONTE VEDRA, Fla., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the

Treace Medical Concepts, Inc. sells medical device treatments for foot bunions. The global market for bunion correction systems is forecasted to reach $1.25 billion by 2030. Treace Medical's financial

Company to Host Conference Call on Thursday, November 9, 2023 at 4:30 pm ET Company to Host Conference Call on Thursday, November 9, 2023 at 4:30 pm ET

PONTE VEDRA, Fla., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the

Treace Medical Concepts continues to present with attractive economic characteristics. TMCI has penetrated 5.8% of the $5bn US bunion surgery market, with management revising FY'23 revenue guidance to

PONTE VEDRA, Fla., July 18, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment o

Treace Medical Concepts, Inc. (NASDAQ:TMCI ) Q1 2023 Earnings Conference Call May 8, 2023 4:30 PM ET Company Participants Vivian Cervantes - IR, Gilmartin Group John Treace - CEO Mark Hair - CFO Confe